Dr. Ingmar Bruns

Chief Medical Officer

Dr. Bruns has 17 years of experience in hematology and oncology including patient care, basic, translational and clinical research. Most recently, he served as the senior vice president and head of clinical development at Pieris Pharmaceuticals, a clinical stage biotechnology company, where he built and led the clinical development organization. From 2013 through October 2017, Dr. Bruns led clinical development of several high priority oncology assets at Bayer Pharmaceuticals. Before his industry tenure, Dr. Bruns served as an attending hematologist and oncologist as well as a physician-scientist at the University Hospital of Dusseldorf in Germany and Albert Einstein College of Medicine in New York. Dr. Bruns has authored over 50 papers in the field of hematology and oncology including several lead authorships in high impact journals such as Nature Medicine, Blood and Leukemia amongst others. He received his M.D. and Ph.D. from the University of Lübeck in Germany.